Variant of antihemophilic factor viii having increased specific activity
AssigneesBaxter Heathcare SA, Baxter International Inc.
InventorsChee K. Lai, Roddy Kevin Stafford
Life of this patent
Estimating the term…
Abstract
The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor VIII having increased specific activity in comparison to known factor VIII products.
Claims35
An isolated and recombinant, fully or partially B-domain deleted factor VIII (FVIII) variant, the FVIII variant being devoid of an amino acid sequence corresponding to amino acids 716 to 742 of porcine factor VIII as depicted in FIG. 2 or amino acids 714 to 740 of SEQ ID NO:
- 7.
An isolated and recombinant, fully or partially B-domain deleted factor VIII (FVIII) variant, the FVIII variant being devoid of an amino acid sequence corresponding to amino acids 716 to 742 of human factor VIII as depicted in FIG. 2 or amino acids 714 to 740 of SEQ ID NO:
- 8.
(canceled)
Dependencies are inferred from the claim text.